Nephros, Inc. (NEPH)
USD 1.9
(1.6%)
USD 1.9
(1.6%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.5 Million USD | 65.39% |
| 2022 | 2.11 Million USD | -26.99% |
| 2021 | 2.9 Million USD | -1.23% |
| 2020 | 2.93 Million USD | -25.46% |
| 2019 | 3.94 Million USD | 4.79% |
| 2018 | 3.76 Million USD | 23.97% |
| 2017 | 3.03 Million USD | 50.82% |
| 2016 | 2.01 Million USD | 53.98% |
| 2015 | 1.3 Million USD | -85.57% |
| 2014 | 9.05 Million USD | 158.65% |
| 2013 | 3.49 Million USD | -15.13% |
| 2012 | 4.12 Million USD | 60.24% |
| 2011 | 2.57 Million USD | 76.84% |
| 2010 | 1.45 Million USD | 109.65% |
| 2009 | 694 Thousand USD | -53.79% |
| 2008 | 1.5 Million USD | 13.02% |
| 2007 | 1.32 Million USD | -81.7% |
| 2006 | 7.26 Million USD | 197.04% |
| 2005 | 2.44 Million USD | -4.36% |
| 2004 | 2.55 Million USD | -75.46% |
| 2003 | 10.41 Million USD | 12.31% |
| 2002 | 9.27 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.17 Million USD | -1.92% |
| 2024 Q1 | 3.23 Million USD | -7.62% |
| 2023 Q3 | 2.29 Million USD | 32.7% |
| 2023 Q2 | 1.73 Million USD | -14.85% |
| 2023 Q1 | 2.03 Million USD | -4.01% |
| 2023 FY | 3.5 Million USD | 65.39% |
| 2023 Q4 | 3.5 Million USD | 52.5% |
| 2022 Q1 | 2.12 Million USD | -26.71% |
| 2022 Q3 | 1.75 Million USD | -29.05% |
| 2022 Q4 | 2.11 Million USD | 20.75% |
| 2022 FY | 2.11 Million USD | -26.99% |
| 2022 Q2 | 2.47 Million USD | 16.27% |
| 2021 FY | 2.9 Million USD | -1.23% |
| 2021 Q2 | 3 Million USD | 25.05% |
| 2021 Q3 | 2.49 Million USD | -17.0% |
| 2021 Q4 | 2.9 Million USD | 16.51% |
| 2021 Q1 | 2.39 Million USD | -18.32% |
| 2020 Q3 | 3.8 Million USD | -13.06% |
| 2020 Q1 | 4.65 Million USD | 18.22% |
| 2020 Q2 | 4.37 Million USD | -6.12% |
| 2020 Q4 | 2.93 Million USD | -22.75% |
| 2020 FY | 2.93 Million USD | -25.46% |
| 2019 Q2 | 5.2 Million USD | 14.87% |
| 2019 FY | 3.94 Million USD | 4.79% |
| 2019 Q3 | 4.83 Million USD | -7.22% |
| 2019 Q4 | 3.94 Million USD | -18.46% |
| 2019 Q1 | 4.53 Million USD | 20.59% |
| 2018 Q1 | 2.73 Million USD | -9.86% |
| 2018 Q4 | 3.76 Million USD | -29.55% |
| 2018 FY | 3.76 Million USD | 23.97% |
| 2018 Q2 | 2.34 Million USD | -14.16% |
| 2018 Q3 | 5.33 Million USD | 127.4% |
| 2017 Q3 | 2.55 Million USD | 24.34% |
| 2017 Q2 | 2.05 Million USD | 8.03% |
| 2017 Q4 | 3.03 Million USD | 18.52% |
| 2017 FY | 3.03 Million USD | 50.82% |
| 2017 Q1 | 1.9 Million USD | -5.27% |
| 2016 Q1 | 1.43 Million USD | 9.8% |
| 2016 Q3 | 1.79 Million USD | -22.78% |
| 2016 Q2 | 2.32 Million USD | 61.92% |
| 2016 FY | 2.01 Million USD | 53.98% |
| 2016 Q4 | 2.01 Million USD | 12.16% |
| 2015 Q2 | 9.32 Million USD | 16.02% |
| 2015 FY | 1.3 Million USD | -85.57% |
| 2015 Q1 | 8.03 Million USD | -11.24% |
| 2015 Q4 | 1.3 Million USD | -13.68% |
| 2015 Q3 | 1.51 Million USD | -83.77% |
| 2014 Q4 | 9.05 Million USD | 159.24% |
| 2014 Q2 | 2.13 Million USD | -6.85% |
| 2014 Q1 | 2.29 Million USD | -34.47% |
| 2014 FY | 9.05 Million USD | 158.65% |
| 2014 Q3 | 3.49 Million USD | 63.44% |
| 2013 Q4 | 3.49 Million USD | 64.58% |
| 2013 Q3 | 2.12 Million USD | 4.16% |
| 2013 FY | 3.49 Million USD | -15.13% |
| 2013 Q2 | 2.04 Million USD | -53.96% |
| 2013 Q1 | 4.43 Million USD | 7.52% |
| 2012 Q2 | 3.45 Million USD | 34.58% |
| 2012 Q3 | 3.63 Million USD | 5.24% |
| 2012 Q4 | 4.12 Million USD | 13.49% |
| 2012 Q1 | 2.56 Million USD | -0.31% |
| 2012 FY | 4.12 Million USD | 60.24% |
| 2011 Q3 | 1.03 Million USD | 82.33% |
| 2011 Q1 | 867 Thousand USD | -40.41% |
| 2011 Q2 | 566 Thousand USD | -34.72% |
| 2011 FY | 2.57 Million USD | 76.84% |
| 2011 Q4 | 2.57 Million USD | 149.32% |
| 2010 Q2 | 867 Thousand USD | -1.14% |
| 2010 Q1 | 877 Thousand USD | 26.37% |
| 2010 FY | 1.45 Million USD | 109.65% |
| 2010 Q4 | 1.45 Million USD | 64.59% |
| 2010 Q3 | 884 Thousand USD | 1.96% |
| 2009 FY | 694 Thousand USD | -53.79% |
| 2009 Q3 | 867 Thousand USD | -6.57% |
| 2009 Q1 | 1.41 Million USD | -6.06% |
| 2009 Q2 | 928 Thousand USD | -34.23% |
| 2009 Q4 | 694 Thousand USD | -19.95% |
| 2008 FY | 1.5 Million USD | 13.02% |
| 2008 Q4 | 1.5 Million USD | -21.85% |
| 2008 Q3 | 1.92 Million USD | -24.3% |
| 2008 Q2 | 2.53 Million USD | 65.73% |
| 2008 Q1 | 1.53 Million USD | 15.27% |
| 2007 Q3 | 19.83 Million USD | 169.7% |
| 2007 Q4 | 1.32 Million USD | -93.3% |
| 2007 Q1 | 6.85 Million USD | -5.59% |
| 2007 Q2 | 7.35 Million USD | 7.25% |
| 2007 FY | 1.32 Million USD | -81.7% |
| 2006 Q3 | 6.91 Million USD | -0.94% |
| 2006 Q4 | 7.26 Million USD | 5.06% |
| 2006 FY | 7.26 Million USD | 197.04% |
| 2006 Q1 | 2.44 Million USD | -0.17% |
| 2006 Q2 | 6.97 Million USD | 185.92% |
| 2005 Q3 | 2.76 Million USD | 0.45% |
| 2005 Q2 | 2.74 Million USD | 8.97% |
| 2005 FY | 2.44 Million USD | -4.36% |
| 2005 Q1 | 2.52 Million USD | -1.35% |
| 2005 Q4 | 2.44 Million USD | -11.43% |
| 2004 Q4 | 2.55 Million USD | -36.31% |
| 2004 FY | 2.55 Million USD | -75.46% |
| 2004 Q2 | 15.81 Million USD | 0.0% |
| 2004 Q3 | 4.01 Million USD | -74.63% |
| 2003 FY | 10.41 Million USD | 12.31% |
| 2002 FY | 9.27 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 126.59 Million USD | 97.233% |
| AngioDynamics, Inc. | 112.08 Million USD | 96.875% |
| AtriCure, Inc. | 147.76 Million USD | 97.629% |
| Avinger, Inc. | 19.97 Million USD | 82.46% |
| Azenta, Inc. | 351.22 Million USD | 99.003% |
| BioLife Solutions, Inc. | 75.05 Million USD | 95.333% |
| The Cooper Companies, Inc. | 4.1 Billion USD | 99.915% |
| Daxor Corporation | 858.75 Thousand USD | -307.915% |
| Ekso Bionics Holdings, Inc. | 16.31 Million USD | 78.525% |
| Femasys Inc. | 9.4 Million USD | 62.747% |
| GlucoTrack, Inc. | 1.7 Million USD | -105.094% |
| Harvard Bioscience, Inc. | 64.29 Million USD | 94.551% |
| Hologic, Inc. | 4.02 Billion USD | 99.913% |
| ICU Medical, Inc. | 2.25 Billion USD | 99.845% |
| Intuitive Surgical, Inc. | 2.04 Billion USD | 99.829% |
| KORU Medical Systems, Inc. | 8.1 Million USD | 56.791% |
| LeMaitre Vascular, Inc. | 48.87 Million USD | 92.833% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -430.809% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -430.809% |
| Masimo Corporation | 1.67 Billion USD | 99.791% |
| Microbot Medical Inc. | 3.82 Million USD | 8.442% |
| Meihua International Medical Technologies Co., Ltd. | 25.07 Million USD | 86.031% |
| Merit Medical Systems, Inc. | 1.12 Billion USD | 99.688% |
| NovoCure Limited | 783.63 Million USD | 99.553% |
| NEXGEL, Inc. | 4.78 Million USD | 26.853% |
| NEXGEL, Inc. | 4.78 Million USD | 26.853% |
| Singular Genomics Systems, Inc. | 86.46 Million USD | 95.948% |
| OraSure Technologies, Inc. | 52.17 Million USD | 93.286% |
| Pro-Dex, Inc. | 23.34 Million USD | 84.993% |
| Pulse Biosciences, Inc. | 16.44 Million USD | 78.697% |
| Predictive Oncology Inc. | 6.14 Million USD | 42.999% |
| Precision Optics Corporation, Inc. | 6.84 Million USD | 48.822% |
| QuidelOrtho Corporation | 3.55 Billion USD | 99.902% |
| Repligen Corporation | 853.2 Million USD | 99.589% |
| Sanara MedTech Inc. | 29.28 Million USD | 88.037% |
| STAAR Surgical Company | 102.73 Million USD | 96.59% |
| Sharps Technology, Inc. | 3.85 Million USD | 9.131% |
| Utah Medical Products, Inc. | 7.14 Million USD | 50.973% |
| DENTSPLY SIRONA Inc. | 4.07 Billion USD | 99.914% |
| Jin Medical International Ltd. | 8.92 Million USD | 60.748% |